Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Targeting EZH2 May Prevent Development of B-cell Lymphomas

By BiotechDaily International staff writers
Posted on 30 May 2013
Image: Senior author Dr. Ari Melnick (Photo courtesy of Weill Cornell Medical College).
Image: Senior author Dr. Ari Melnick (Photo courtesy of Weill Cornell Medical College).
A "master regulator" gene has been identified in immune system B-cell lymphocytes that when mutated fails to maintain the normal cell phenotype, which prompts the B-cells to enter a phase of uncontrolled cell division that results in the type of cancer known as B-cell lymphoma.

Most B-cell lymphomas arise from germinal center (GC) B-cells, since they divide rapidly while at the same time mutating their antibody genes. In some cases other genes become mutated as well, which can eventually result in lymphoma formation. GCs are sites within lymph nodes where mature B lymphocytes rapidly proliferate, differentiate, mutate their antibodies, and class switch their antibodies during a normal immune response to an infection. GCs are an important part of the B-cell humoral immune response, and they develop dynamically after the activation of B-cells by T-dependent antigen.

Investigators at Weill Cornell Medical College (New York, NY, USA) examined the role of the protein encoded by the EZH2 (enhancer of zeste homolog 2, also known as histone-lysine N-methyltransferase) gene, which is highly expressed in GC B-cells, in the process leading up to lymphoma formation.

They reported in the May 13, 2013, issue of the journal Cancer Cell that EZH2 repressed proliferation checkpoint genes and helped establish chromatin domains at key regulatory loci to transiently block the differentiation of B-cells away from the GC phenotype. Genomic deletion or pharmacologic suppression of EZH2 expression with a chemical inhibitor suppressed GC formation and function.

"EZH2 is a master regulator protein that turns off the brakes that prevent cell division, so it allows cells to divide without stopping," said senior author Dr. Ari Melnick, professor of medicine at Weill Cornell Medical College. "EZH2 prevents germinal cells from transitioning to antibody-secreting cells. Indeed, in the normal immune system EZH2 prevents B-cells from exiting germinal centers so that these cells can continue to undergo sustained rapid cell division, which continues until the immune system says to stop. Then EZH2 goes away, and B-cells can develop into antibody-secreting cells, which send antibodies into the circulation to fight off infection. Germinal center cells absolutely require EZH2 and the lymphomas that arise from germinal center cells inherit that need regardless of whether they have mutations."

"Researchers had thought EZH2 inhibitors would only help patients with a mutation in their EZH2 gene, which represents a small subset of lymphoma patients. What we found is that a majority of lymphomas turn out to be dependent on normal EZH2, not just mutated EZH2," said Dr. Melnick. "Our research indicates that these inhibitors will be remarkably effective. I am very optimistic."

Related Links:

Weill Cornell Medical College



Channels

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.